ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Dr. James Murtagh, Advancing Medical Research through Advocacy

Los Angeles, California, United States - 02-27-2023 (PR Distribution™) -

Serving as a medical research advocate remains a high priority for Dr. James Murtagh. Now in his fifth decade as a doctor in 2023, he spends a significant amount of time outside the office conducting research and posting written pieces online. 

As a practicing doctor interested in medical research since 1982, he’s paying close attention to new developments related to the pulmonary disease and sleep disorder fields he specializes in.

Medical research is nothing new for Dr. James Murtagh. He worked as a staff scientist for the US Department of Health and Human Services Research Agency right after graduating from medical school, and he’s never looked back. He’s always stuck to a high level of healthcare morality and ethics, providing clinically-tested solutions for patients.

So far, in 2023, two clinical trials have caught Dr. James Murtagh’s attention. The first is a safe treatment for sleeping sickness. Commonly referred to as African trypanosomiasis, his experience in sleep disorders has him curious about the endemic that’s been hindering different parts of Africa. 

Any disease causing problems while a person can be deadly at a time when the average person is most vulnerable.

An all-oral medication is being evaluated and researched thoroughly in 2023. It’s looking to replace an arsenic derivative used to treat sleeping sickness for decades. A much safer solution, it has a chance to be a significant game-changer for those dealing with this potentially fatal disease.

COVID-19-related solutions in the medical field continue to come out, and they matter greatly to Dr. James Murtagh. As stated in an interview with ideamench.com, he saw 100% of COVID-19 patients during the peak pandemic years. Clinical trials are currently going on for a COVID-19 vaccination for HIV-infected people. 

They are researching how well the Moderna vaccine works in fighting COVID-19 in adults diagnosed with HIV. As different parts of the world look to provide viral clearance for the immunocompromised, adults dealing with HIV will better understand how many doses work for them.

Thanks to medical researchers like Dr. James Murtagh and others, advancements happen to help patients more than ever. He fully embraces the technological aspect of healthcare but always wants it done the right way.

Healthcare developments, and medical research, in general, are moving at a faster pace than ever before. As medical professionals have strong morality and ethics, Dr. James Murtagh is very supportive. 

He knows that advancements in any specialty medical field can impact the lives of so many. Every new release has the chance to prevent serious illness, complications, or even death.

Dr. James Mutagh posts many updates that will catch his attention in the medical field and any new writing on his website, Twitter account, JamesMurtaghMD, or LinkedIn page. 2023 is another big year for clinical trials and medical breakthroughs so that others might grab his attention later in the year.

Media Contacts:

Company Name: Todays News Media
Full Name: Roger Martinez
Phone: 2134768890
Email Address: Send Email
Website: http://todaysnewsmedia.com

For the original news story, please visit https://www.prdistribution.com/news/dr-james-murtagh-advancing-medical-research-through-advocacy/9561123.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.